SISRAM MED (01696) intends to conduct internal restructuring of its controlling shareholder.

SISRAM MED (01696) announced that on April 8, 2026, the board of directors received a notification from the company's controlling shareholder, Shanghai Fosun Pharmaceutical (Group) Co., Ltd., to optimize the internal equity structure. On that day, Shanghai Fosun Pharmaceutical's two indirect wholly-owned subsidiaries, Nengyue Limited (Nengyue) and Mezhonghuli Medical Limited (Mezhonghuli), signed a share transfer agreement with another Shanghai Fosun Pharmaceutical indirect wholly-owned subsidiary, Fosun Pharma Industrial Pte. Ltd. (FPI). According to the agreement, Nengyue agreed to transfer all of its 207,186,160 shares of the company (approximately 44.24% of the total issued shares as of the date of this announcement), and Mezhonghuli agreed to transfer all of its 127,318,640 shares of the company (approximately 27.18% of the total issued shares as of the date of this announcement) to FPI. The completion of the proposed restructuring is subject to several conditions being met. Upon completion of the proposed restructuring, FPI will acquire 71.42% of the company's voting rights, triggering the mandatory general offer obligation under the takeover code. Accordingly, Shanghai Fosun Pharmaceutical has applied for, and the Securities and Futures Commission has approved, an exemption from the obligation to make a general offer for the company's shares as a result of this proposed restructuring.